Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks to 17 years of age.
The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as the variability of serotype epidemiology in different geographical areas.
The immunisation schedules for Prevenar 13 should be based on official recommendations.
Infants who receive a first dose of Prevenar 13 should complete the vaccination course with Prevenar 13.
Prevenar 13 can be co-administered with other routine paediatric vaccines administered as part of the UK national immunisation programme.
Burden of disease
Infants and children aged 6 weeks to 5 years
In England and Wales, prior to the introduction of the pneumococcal conjugate vaccine (Prevenar, Pneumococcal polysaccharide conjugate vaccine (7-valent), PCV7) to the national immunisation programme (NIP), the incidence of invasive pneumococcal disease (IPD) was highest in <2 -years-olds (36/100000 in 2005-2006) and the serotypes included in PCV7 were responsible for 73% of IPD.
- Since the introduction of PCV7 to the NIP in 2006, in England and Wales there has been an overall 37% reduction in IPD incidence.
- There has been a further 7% reduction since the introduction of Prevenar 13.
- It has been estimated that almost 40,000 cases of IPD have been prevented since the start of the pneumococcal conjugate vaccine programme.
Children and adolescents aged 6 to 17 years
In children and adolescents aged 6 to 17 years, the incidence of pneumococcal disease is low, however, there is an increased risk of morbidity and mortality in those with underlying comorbidities.